Vienna, Austria: it’s day 2 of the European Cancer Congress in Vienna (Twitter #ECC2015).
Along with 18,000+ attendees we’re looking forward to hearing about some more practice changing data.
Today in Vienna brings another busy and jam packed day at the European Cancer Conference (ECC). We’ve already reached the point where the days blur and you have no idea which day of the week it actually is, you just follow the next fresh day in your personalised program or schedule.
So what’s in store today?
This morning brings updates on lung cancer, including the much anticipated atezolizumab results in POPLAR and BIRCH, as well as urothelial bladder cancer from the IMVigor trial. There is also a melanoma session that includes the oncolytic virus T-VEC, together with pembrolizunab and cobimetinib in separate study readouts. All this before lunch!
The afternoon promises to be equally interesting with an Immunotherapy in Cancer session that includes nivolumab, pembrolizumab plus we get our first look at a novel immunocytokine targeting CEA-IL2. A parallel session explores the science behind brain tumours with presentations on the tumour microenvironment, biomarkers and current trials.
In the meantime, the embargoes lift at 7am CEST on several studies including the atezolizumab data, which we highlight here.
To learn more about our insights throughout the day, including the latest immuno-oncology perspectives – some of which is potentially practice changing – subscribers can log-in or you can sign up in the box below.